Estradiol, tamoxifen, and flaxseed alter IL-1β and IL-1Ra levels in normal human breast tissue in vivo.

INTRODUCTION Sex steroid exposure increases the risk of breast cancer by unclear mechanisms. Diet modifications may be one breast cancer prevention strategy. The proinflammatory cytokine family of IL-1 is implicated in cancer progression. IL-1Ra is an endogenous inhibitor of the proinflammatory IL-1α and IL-1β. OBJECTIVE The objective of this study was to elucidate whether estrogen, tamoxifen, and/or diet modification altered IL-1 levels in normal human breast tissue. DESIGN AND METHODS Microdialysis was performed in healthy women under various hormone exposures, tamoxifen therapy, and diet modifications and in breast cancers of women before surgery. Breast tissue biopsies from reduction mammoplasties were cultured. RESULTS We show a significant positive correlation between estradiol and in vivo levels of IL-1β in breast tissue and abdominal sc fat, whereas IL-1Ra exhibited a significant negative correlation with estradiol in breast tissue. Tamoxifen or a dietary addition of 25 g flaxseed per day resulted in significantly increased levels of IL-1Ra in the breast. These results were confirmed in ex vivo culture of breast biopsies. Immunohistochemistry of the biopsies did not reveal any changes in cellular content of the IL-1s, suggesting that mainly the secreted levels were affected. In breast cancer patients, intratumoral levels of IL-1β were significantly higher compared with normal adjacent breast tissue. CONCLUSION IL-1 may be under the control of estrogen in vivo and may be attenuated by antiestrogen therapy and diet modifications. The increased IL-1β in breast cancers of women strongly suggests IL-1 as a potential therapeutic target in breast cancer treatment and prevention.

[1]  F. Boccardo,et al.  Serum enterolactone levels and mortality outcome in women with early breast cancer: a retrospective cohort study , 2012, Breast Cancer Research and Treatment.

[2]  J. Chang-Claude,et al.  Serum enterolactone and prognosis of postmenopausal breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Saarinen,et al.  Tamoxifen and Flaxseed Alter Angiogenesis Regulators in Normal Human Breast Tissue In Vivo , 2011, PloS one.

[4]  J. Chang-Claude,et al.  Estimated enterolignans, lignan-rich foods, and fibre in relation to survival after postmenopausal breast cancer , 2011, British Journal of Cancer.

[5]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[6]  A. Tjønneland,et al.  Prediagnostic plasma enterolactone levels and mortality among women with breast cancer , 2011, Breast Cancer Research and Treatment.

[7]  N. Saarinen,et al.  Estrogen‐induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo , 2010, International journal of cancer.

[8]  C. Dinarello.  Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.

[9]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  C. Dabrosin,et al.  In vivo measurement of tumor estradiol and Vascular Endothelial Growth Factor in breast cancer patients , 2008, BMC Cancer.

[11]  Q. Cai,et al.  Estrogen-Induced Generation of Reactive Oxygen and Nitrogen Species, Gene Damage, and Estrogen-Dependent Cancers , 2007, Journal of toxicology and environmental health. Part B, Critical reviews.

[12]  F. Clavel-Chapelon,et al.  Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status. , 2007, Journal of the National Cancer Institute.

[13]  C. Dabrosin,et al.  Flaxseed and Its Lignans Inhibit Estradiol-Induced Growth, Angiogenesis, and Secretion of Vascular Endothelial Growth Factor in Human Breast Cancer Xenografts In vivo , 2007, Clinical Cancer Research.

[14]  Chin-Yo Lin,et al.  Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. , 2006, Cancer research.

[15]  B. Trock,et al.  Meta-analysis of soy intake and breast cancer risk. , 2006, Journal of the National Cancer Institute.

[16]  Y. Carmi,et al.  Effects of micro-environment- and malignant cell-derived interleukin-1 in carcinogenesis, tumour invasiveness and tumour-host interactions. , 2006, European journal of cancer.

[17]  C. Dabrosin,et al.  Positive Correlation between Estradiol and Vascular Endothelial Growth Factor but not Fibroblast Growth Factor-2 in Normal Human Breast Tissue In vivo , 2005, Clinical Cancer Research.

[18]  R. Strieter,et al.  Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1 beta-induced neovascularization and tumor growth. , 2005, The Journal of clinical investigation.

[19]  K. Strasser-Weippl,et al.  Dietary Flaxseed Alters Tumor Biological Markers in Postmenopausal Breast Cancer , 2005, Clinical Cancer Research.

[20]  C. Dabrosin.  Microdialysis - an in vivo technique for studies of growth factors in breast cancer. , 2005, Frontiers in bioscience : a journal and virtual library.

[21]  L. Brinton,et al.  Global trends in breast cancer incidence and mortality 1973-1997. , 2005, International journal of epidemiology.

[22]  M. Pike,et al.  Prevention of cancers of the breast, endometrium and ovary , 2004, Oncogene.

[23]  Smadar Cohen,et al.  A continuous delivery system of IL‐1 receptor antagonist reduces angiogenesis and inhibits tumor development , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  C. Dabrosin.  Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. , 2003, The Journal of clinical endocrinology and metabolism.

[25]  Y. Iwakura,et al.  IL-1 is required for tumor invasiveness and angiogenesis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.

[27]  S. Wray,et al.  17-β-Estradiol regulates expression of genes that function in macrophage activation and cholesterol homeostasis , 2002, The Journal of Steroid Biochemistry and Molecular Biology.

[28]  L. Thompson,et al.  Dietary Flaxseed Inhibits Human Breast Cancer Growth and Metastasis and Downregulates Expression of Insulin-Like Growth Factor and Epidermal Growth Factor Receptor , 2002, Nutrition and cancer.

[29]  C. Dabrosin.  Technical aspects of microdialysis of human breast , 2001, Scandinavian journal of clinical and laboratory investigation.

[30]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[31]  C. Bellone,et al.  Effect of estrogens on IL-1β promoter activity , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[32]  Welch Hg,et al.  Using Autopsy Series To Estimate the Disease “Reservoir” for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find? , 1997 .

[33]  Liang Jin,et al.  Expression of interleukin‐1β in human breast carcinoma , 1997 .

[34]  U. Ungerstedt,et al.  Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an in vivo study with microdialysis technique. , 1997, The Journal of clinical endocrinology and metabolism.

[35]  U. Ungerstedt,et al.  Microdialysis of human breast tissue during the menstrual cycle. , 1997, Clinical science.

[36]  B. Hulka,et al.  Breast cancer: cause and prevention , 1995, The Lancet.

[37]  B. Modan,et al.  Dietary factors and risk of breast cancer: combined analysis of 12 case-control studies. , 1990, Journal of the National Cancer Institute.

[38]  G. Lindahl,et al.  Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer. , 2011, Cancer research.